数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of pain, disability, and healthcare utilization worldwide, responsible for a substantial clinical and socioeconomic burden on society.
方法
Still, significant challenges remain in identifying appropriate patient populations and generating the high-quality evidence necessary to bring disease-modifying therapies into clinical practice.
核心结论
However, advances in the understanding of OA pathogenesis have led to the emergence of therapeutic strategies targeting metabolic dysfunction, inflammation, tissue repair, and pain pathways.；The present review highlights recent developments in OA management including repurposed metabolic and anti-rheumatic therapies, regenerative approaches such as platelet-rich plasma (PRP) and mesenchymal stem cells, minimally invasive interventional procedures, and emerging biologic and gene therapies.；The increased recognition of distinct OA phenotypes has led to the opportunity to translate these discoveries into precision medicine approaches. ‖ 结论：The increased recognition of distinct OA phenotypes has led to the opportunity to translate these discoveries into precision medicine approaches.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★☆☆☆ 衰弱/肌少症是少有的已有监管认可终点的老年综合征，是临床转化的最短路径。
原文题录
- 英文标题：New developments in the management of osteoarthritis.
- 期刊与标识：Best Pract Res Clin Rheumatol · PMID 42946578 · DOI 10.1016/j.berh.2026.102211**
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。